Activation of ACLY by SEC63 deploys metabolic reprogramming to facilitate hepatocellular carcinoma metastasis upon endoplasmic reticulum stress

Chen-Yu Hu, Zechang Xin, Xiaoyan Sun, Yang Hu, Chunfeng Zhang, Rui Yan, Yuying Wang, Min Lu, Jing Huang, Xiaojuan Du, Baocai Xing, Xiaofeng LiuJournal of Experimental & Clinical Cancer Research 2023 · DOI

Abstract

Our findings revealed that SEC63-mediated metabolic reprogramming plays important roles in keeping ER homeostasis upon stimuli in HCC cells. Meanwhile, SEC63 coordinates with ACLY to upregulate the expression of Snail1, which further promotes HCC metastasis. Metastasis is crucial for helping cancer cells seek new settlements upon microenvironmental stimuli. Taken together, our findings highlight a cancer selective adaption to ER stress as well as reveal the potential roles of the IRE1α-SEC63-ACLY axis in HCC treatment.

Introduction

Hepatocellular carcinoma (HCC) is a highly aggressive cancer, largely due to its propensity for metastasis. Within the tumor microenvironment, cancer cells frequently encounter endoplasmic reticulum (ER) stress—a condition where misfolded proteins accumulate due to rapid proliferation, hypoxia, and nutrient deprivation. To survive, cells activate the Unfolded Protein Response (UPR). While the UPR typically aims to restore homeostasis, malignant cells often hijack these pathways to drive progression. This study investigates the link between ER stress and metabolic reprogramming, specifically focusing on how cells manage Acetyl-CoA levels to facilitate metastasis under pressure.

Methods

The researchers utilized a multi-disciplinary approach to map the IRE1α-SEC63-ACLY signaling axis:

  • Clinical Correlation: Analysis of SEC63 and ACLY expression in 139 HCC patients (PUCH cohort) and validation using public datasets (TCGA and ICGC).
  • Mechanistic Biochemistry: Identification of protein-protein interactions via Co-Immunoprecipitation (Co-IP), Mass Spectrometry, and GST pull-down assays.
  • Metabolic Profiling: Measurement of Acetyl-CoA, cholesterol, and triglycerides to confirm metabolic shifts.
  • Epigenetic Analysis: ChIP-qPCR to assess histone acetylation at the SNAI1 promoter.
  • In Vivo Models: Mouse lung metastasis models using tail-vein injections and treatment with the ACLY inhibitor ETC1002.

Results

Data Integration and Clinical Significance

To identify key players in HCC progression, the authors integrated multiple genomic datasets. A Venn diagram illustrates the overlap of differentially expressed genes across the TCGA-LIHC, ICGC-LIRI-JP, and GSE101728 cohorts, highlighting candidates consistently associated with HCC progression across different populations.

Venn diagram showing the overlap of genes across TCGA, ICGC, and GSE101728 datasets.

Clinical analysis revealed that high expression of both SEC63 and ACLY significantly correlates with advanced tumor stages and shorter overall survival (P < 0.0001).

The IRE1α-SEC63-ACLY Axis

The study identified a novel signaling axis triggered by ER stress. Upon induction of ER stress by agents like Tunicamycin (TM) or Thapsigargin (TG), the sensor IRE1α phosphorylates SEC63 at T537. This phosphorylation enables SEC63 to interact with ACLY (ATP-citrate lyase).

SEC63 interacts with ACLY under ER stress conditions in HCC cells.

As shown in Figure 6, mass spectrometry identified SEC63 as a top ER-related protein interacting with ACLY (Panel G). Co-IP experiments confirmed this interaction in Huh7 cells (Panel H) and demonstrated that the interaction is enhanced under ER stress conditions (Panel I). By binding to ACLY, SEC63 shields it from ubiquitin-mediated degradation by the KLHL25/CUL3 complex, thereby stabilizing ACLY levels.

Metabolic and Epigenetic Reprogramming

Stabilized ACLY leads to a surge in cellular Acetyl-CoA, which serves two primary functions:

  1. Cytoplasmic Survival: Increased Acetyl-CoA fuels lipid synthesis, supporting ER membrane expansion to alleviate protein folding stress.
  2. Nuclear Metastasis: SEC63 and ACLY translocate to the nucleus, where elevated Acetyl-CoA levels promote histone acetylation. Specifically, acetylation of SMAD3 enhances its binding to the Snail1 promoter, triggering the Epithelial-Mesenchymal Transition (EMT) and driving metastasis.

In Vivo Validation

In mouse models, SEC63 deficiency significantly reduced lung metastatic lesions. Furthermore, the pro-metastatic effects of SEC63 overexpression were almost entirely reversed by inhibiting ACLY with ETC1002, confirming ACLY as the primary engine behind this SEC63-driven progression.

Discussion and Future Work

This research identifies SEC63 as a critical "double-agent" that facilitates both survival and metastasis in HCC under ER stress. While the study provides a robust mechanism, some questions remain. The T537A mutation only partially restored ACLY degradation, suggesting other post-translational modifications may be involved. Additionally, the simultaneous transcriptional regulation of SEC63 and ACLY remains to be fully elucidated. Future work should explore the therapeutic potential of targeting the IRE1α-SEC63-ACLY axis in clinical settings, potentially repurposing existing ACLY inhibitors like Bempedoic acid for HCC treatment.

Summary updated

Abstract

Our findings revealed that SEC63-mediated metabolic reprogramming plays important roles in keeping ER homeostasis upon stimuli in HCC cells. Meanwhile, SEC63 coordinates with ACLY to upregulate the expression of Snail1, which further promotes HCC metastasis. Metastasis is crucial for helping cancer cells seek new settlements upon microenvironmental stimuli. Taken together, our findings highlight a cancer selective adaption to ER stress as well as reveal the potential roles of the IRE1α-SEC63-ACLY axis in HCC treatment.
BibTeX
@article{hu2023activation,
  author = {Chen-Yu Hu and Zechang Xin and Xiaoyan Sun and Yang Hu and Chunfeng Zhang and Rui Yan and Yuying Wang and Min Lu and Jing Huang and Xiaojuan Du and Baocai Xing and Xiaofeng Liu},
  title = {{Activation of ACLY by SEC63 deploys metabolic reprogramming to facilitate hepatocellular carcinoma metastasis upon endoplasmic reticulum stress}},
  journal = {Journal of Experimental \& Clinical Cancer Research},
  year = {2023},
  doi = {10.1186/s13046-023-02656-7},
}
Figure